文献速递妇科生殖医学

沙格列汀/二甲双胍缓释片联合短期治疗优于单药治疗糖尿病前期多囊卵巢综合征女性:单盲随机预试验

Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
PubMed 文献 · Fertil Steril · 2016-10-27

这项前瞻性、随机、单盲预试验纳入38例多囊卵巢综合征(PCOS)合并糖调节受损的糖尿病前期高血糖女性,随机接受沙格列汀/二甲双胍缓释片联合(5 mg/2000 mg)、沙格列汀(5 mg)或二甲双胍缓释片(2000 mg)治疗16周,34例完成研究。联合治疗组糖耐量恢复正常比例(91%)高于二甲双胍组(25%),胰岛素分泌-敏感性指数和月经规律性改善也优于二甲双胍单药。

要点

  • 联合组10/11(91%)糖耐量恢复正常,二甲双胍组3/12(25%),联合组优于二甲双胍组
  • 联合组胰岛素分泌-敏感性指数和月经规律性改善显著优于二甲双胍单药
  • 甘油三酯、甘油三酯/高密度脂蛋白胆固醇比值和平均血糖仅在联合组和沙格列汀组显著下降

核心结论

  • 在糖尿病前期PCOS患者中,沙格列汀/二甲双胍缓释片联合治疗在临床和代谢获益方面优于任一单药治疗。

研究设计与样本

  • 前瞻性、随机、单盲药物研究,纳入38例18-42岁经75克口服葡萄糖耐量试验确定为糖尿病前期高血糖的PCOS患者,随机接受沙格列汀/二甲双胍缓释片(5 mg/2000 mg)、沙格列汀(5 mg)或二甲双胍缓释片(2000 mg)治疗16周,34例完成研究。

主要发现

  • 研究完成时19例糖耐量正常:二甲双胍组3/12(25%)、沙格列汀组6/11(55%)、联合组10/11(91%),联合组在统计学上优于二甲双胍组。
  • 所有组的体重指数、腰围、腰高比、游离雄激素指数、胰岛素敏感性、胰岛素分泌-敏感性指数和月经均改善,但联合组胰岛素分泌-敏感性指数和月经规律性显著优于二甲双胍组。
  • 甘油三酯、甘油三酯/高密度脂蛋白胆固醇比值和平均血糖仅在联合组和沙格列汀组显著下降。

关键数值与推荐

  • 糖耐量恢复正常比例:联合组10/11(91%)vs 二甲双胍组3/12(25%),联合组统计学优于二甲双胍组。

临床怎么用

  • 作者认为,沙格列汀/二甲双胍缓释片联合治疗在糖尿病前期PCOS患者的临床和代谢获益方面优于任一单药治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate efficacy with the dipeptidyl peptidase-4 inhibitor saxagliptin (SAXA), metformin extended release (MET), and combination (SAXA-MET) in patients with polycystic ovary syndrome (PCOS) and impaired glucose regulation. DESIGN: Prospective, randomized, single-blind drug study. SETTING: Outpatient clinic. PATIENT(S): Patients (n = 38) with PCOS (aged 18-42 years) and prediabetic hyperglycemia determined by a 75-gram oral glucose tolerance test. INTERVENTION(S): Patients were randomized to SAXA-MET (5 mg/2,000 mg), SAXA (5 mg), or MET (2,000 mg) for 16 weeks. MAIN OUTCOME MEASURE(S): Fasting and mean blood glucose, insulin sensitivity, insulin secretion, and insulin secretion-sensitivity index (IS-SI) by oral glucose tolerance tests. Free androgen index and lipid levels, average menstrual interval, and anthropometric measurements (body mass index, waist circumference, and waist/height ratio). RESULT(S): The study was completed by 34 patients. Nineteen patients had normal glucose tolerance: 3 of 12 (25%) on MET; 6 of 11 (55%) on SAXA; and 10 of 11 (91%) on SAXA-MET (SAXA-MET statistically superior to MET) at study completion. Body mass index, waist circumference, waist/height ratio, free androgen index, insulin sensitivity, IS-SI, and menses improved in all groups; however, IS-SI and menstrual regularity were significantly better with SAXA-MET vs. MET treatment. Triglyceride, triglyceride/high-density lipoprotein cholesterol ratio and mean blood glucose significantly declined in the SAXA-MET and SAXA groups only. CONCLUSION(S): This pilot work provides the first evidence regarding the effects of a dipeptidyl peptidase-4 inhibitor alone and in combination with MET in this patient population. Treatment with SAXA-MET was superior to either drug alone in terms of clinical and metabolic benefits in prediabetic patients with PCOS. CLINICAL TRIAL REGISTRATION NUMBER: NCT02022007.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Elkind-Hirsch KE, Paterson MS, Seidemann EL, et al. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study. Fertil Steril. 2016. PMID: 28228317. doi:10.1016/j.fertnstert.2016.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。